2024
Prescription Patterns for Sodium-Glucose Cotransporter 2 Inhibitors in U.S. Health Systems
Shin J, Xu Y, Chang A, Carrero J, Flaherty C, Mukhopadhyay A, Inker L, Blecker S, Horwitz L, Grams M. Prescription Patterns for Sodium-Glucose Cotransporter 2 Inhibitors in U.S. Health Systems. Journal Of The American College Of Cardiology 2024, 84: 683-693. PMID: 39142721, DOI: 10.1016/j.jacc.2024.05.057.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2Class 1A recommendationSodium-glucose cotransporter 2 inhibitor therapyChronic kidney diseaseU.S. health systemHealth systemInhibitor prescriptionHeart failurePrescription ratesInhibitor therapyInhibitor useSodium-glucose cotransporter 2 inhibitorsSodium-glucose cotransporter 2 inhibitor useOptum Labs Data WarehouseProportion of patientsSGLT2 inhibitor usePresence of diabetesRecurrent cardiovascular eventsAtherosclerotic cardiovascular diseaseCotransporter 2Analysis of U.S. dataSevere albuminuriaPrescription patternsCardiovascular eventsCommercial insurance
2020
Trends in COVID‐19 Risk‐Adjusted Mortality Rates
Horwitz LI, Jones SA, Cerfolio RJ, Francois F, Greco J, Rudy B, Petrilli CM. Trends in COVID‐19 Risk‐Adjusted Mortality Rates. Journal Of Hospital Medicine 2020, 16: 90-92. PMID: 33147129, DOI: 10.12788/jhm.3552.Peer-Reviewed Original ResearchConceptsHospital mortalityMortality rateHealth systemRisk-adjusted mortality ratesAdmission vital signsStandardized mortality ratioCoronavirus disease 2019Academic health systemPatient characteristicsClinical factorsMortality ratioDisease 2019High mortalityVital signsMortalityComorbiditiesCOVID-19Laboratory resultsEarlier reportsHospitalizationPatientsHospiceDemographicsFactors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study
Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell L, Chernyak Y, Tobin KA, Cerfolio RJ, Francois F, Horwitz LI. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. The BMJ 2020, 369: m1966. PMID: 32444366, PMCID: PMC7243801, DOI: 10.1136/bmj.m1966.Peer-Reviewed Original ResearchConceptsBody mass indexProspective cohort studyCritical illnessCoronavirus disease 2019Hospital admissionCohort studyHeart failureMale sexDisease 2019Hospice careAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionSyndrome coronavirus 2 infectionC-reactive protein levelsSingle academic medical centerAdmission oxygen saturationCoronavirus 2 infectionReactive protein levelsChronic kidney diseaseD-dimer levelsMarkers of inflammationAge 75 yearsSeverity of illnessStrong riskMultivariable logistic regression
2019
Bending the cost curve: time series analysis of a value transformation programme at an academic medical centre
Chatfield SC, Volpicelli FM, Adler NM, Kim KL, Jones SA, Francois F, Shah PC, Press RA, Horwitz LI. Bending the cost curve: time series analysis of a value transformation programme at an academic medical centre. BMJ Quality & Safety 2019, 28: 449. PMID: 30877149, PMCID: PMC6860728, DOI: 10.1136/bmjqs-2018-009068.Peer-Reviewed Original ResearchConceptsLength of stayDiagnosis Related GroupsAcademic medical centerHospital mortalityMedical CenterMedical diagnosis related groupsSurgical diagnosis related groupsStudy periodSame-hospital readmissionsCost of careNYU Langone HealthVariable direct costsValue of healthcareSecondary outcomesHigh-value careStudy cohortOutlier patientsHealth outcomesValue careEarly increaseIntervention costsDirect costsHealthcare valueShared Savings ProgramHospitalisationTrends in Hospital Readmission of Medicare-Covered Patients With Heart Failure
Blecker S, Herrin J, Li L, Yu H, Grady JN, Horwitz LI. Trends in Hospital Readmission of Medicare-Covered Patients With Heart Failure. Journal Of The American College Of Cardiology 2019, 73: 1004-1012. PMID: 30846093, PMCID: PMC7011858, DOI: 10.1016/j.jacc.2018.12.040.Peer-Reviewed Original ResearchConceptsHospital Readmissions Reduction ProgramSecondary heart failureReadmission ratesHeart failureReadmissions Reduction ProgramHF hospitalizationAffordable Care ActMedicare's Hospital Readmissions Reduction ProgramRisk-adjusted readmission ratesCause readmission rateHigher readmission ratesAcute myocardial infarctionCare ActReduction programsLinear spline regression modelsPneumonia hospitalizationsHospital readmissionMedicare hospitalizationsRetrospective studySecondary diagnosisMyocardial infarctionPrincipal diagnosisHospitalizationSpline regression modelsPatients
2016
Quasi-Experimental Evaluation of the Effectiveness of a Large-Scale Readmission Reduction Program
Jenq GY, Doyle MM, Belton BM, Herrin J, Horwitz LI. Quasi-Experimental Evaluation of the Effectiveness of a Large-Scale Readmission Reduction Program. JAMA Internal Medicine 2016, 176: 681. PMID: 27065180, DOI: 10.1001/jamainternmed.2016.0833.Peer-Reviewed Original ResearchConceptsDischarge patientsReadmissions Reduction ProgramControl populationReadmission ratesIntervention periodSame-hospital readmission ratesUrban academic medical centerTarget populationAdjusted readmission ratesOdds of readmissionHigh-risk patientsZip codesAdjusted admission ratesInterrupted time series analysisAcademic medical centerQuasi-experimental evaluationLogistic regression modelsReduction programsDischarge dispositionReadmission reduction effortsComparative interrupted time series analysisMedication reconciliationService patientsMean ageTransitional care